Alligator Bioscience AB (Alligator)

Oncology Corporate Profile

HQ Location

Medicon Village
223 81 Lund, Sweden

Company Description

Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms ALLIGATOR-GOLD® and FIND®: ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. FIND® (Fragment Induced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ADC-1013IgG agonistic monoclonal antibodyVarious cancer typesIJanssen
ADC-1015bi-specific immuneVarious cancer typesPreclinicalJansenn

View additional information on product candidates here »


Recent News Headlines

There are no news items to display